SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies (Details) (USD $)	3 Months Ended	6 Months Ended							6 Months Ended						3 Months Ended	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Jun. 30, 2012 Pharmacogenomic services	Jun. 30, 2011 Pharmacogenomic services	Jun. 30, 2012 Diagnostic tools	Jun. 30, 2011 Diagnostic tools	Jun. 30, 2012 Additional Paid-in Capital	Jun. 30, 2011 Additional Paid-in Capital	Jun. 30, 2012 Accumulated Other Comprehensive Income (Loss)	Jun. 30, 2012 Minimum	Jun. 30, 2012 Maximum	Jun. 30, 2012 Executive officer	Jun. 30, 2011 Equity incentive plan 2006	Jun. 30, 2012 Equity incentive plan 2006	Jun. 30, 2011 Equity incentive plan 2006
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted, contractual term		10 years
Stock options, unvested options, vesting period												1 year	3 years
Non-cash stock-based compensation		$ 471,000							$ 471,000	$ 800,000	$ 0
Unvested stock options, unrecognized compensation expense	$ 600,000	$ 600,000
Unvested stock options, unrecognized compensation expense weighted average recognition period		3 years
Stock options, granted	49,000	149,000													2,200,000	149,000	2,335,500
Stock options, fair value assumptions, risk free interest rate		1.03%	1.87%
Stock options, fair value assumptions, dividend yield		0.00%	0.00%
Stock options, fair value assumptions, expected life		8 years 2 months 8 days	4 years
Stock options, fair value assumptions, historical volatility rate		111.35%	105.00%
Stock options, fair value assumptions, expected holding period														5 years
Stock options, fair value assumptions, forfeiture rate		1.63%	1.10%
Other accrued liabilities	3,884,000	3,884,000		3,839,000	200,000	100,000	1,300,000	1,400,000
Cumulated foreign currency translation gain	0	0	107,000
Foreign currency transaction gain (loss), realized			$ (100,000)										$ 100,000
Options, warrants and conversion rights, common stock callable and antidilutive		29,416,204	18,504,943